Clinical Trials · NCT06884293
A Study Comparing IBI362 vs Semaglutide in Chinese Overweight or Obese Adults With Metabolic Dysfunction-associated Fatty Liver Disease （MAFLD）
- Phase
- Phase 3
- Recruitment status
- Active Not Recruiting
- Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
- Enrollment
- 479
- Start date
- May 2025
- Locations
- 1 site, China
- Primary endpoint
- percentage change in body weight from baseline